-Bloomberg
Morgan Stanley Maintains Equal-Weight on Exelixis, Lowers Price Target to $22
Morgan Stanley analyst Jeffrey Hung maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and lowers the price target from $23 to $22.
Related Posts
From Benzinga’s Global Small Cap Conference: Pluristem Therapeutics President & CEO, Yaky Yanay Begins Presenting
https://www.youtube.com/watch?v=XkOilNZqoEI
Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease Patients
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has announced results from a new analysis examining obeticholic acid’s (OCA) potential to improve transplant-free survival in…
S&P 500 Rises 100 Points; Nasdaq Up 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.